Utility and Improvement of Liposome Injections AmBisome<sup>®</sup> for Clinical Use

  • SUGIYAMA Ikumi
    School of Pharmacy, Iwate Medical University
  • KUDO Kenzo
    School of Pharmacy, Iwate Medical University Department of Pharmacy, Iwate Medical University Hospital
  • TAKAHASHI Katsuo
    School of Pharmacy, Iwate Medical University Department of Pharmacy, Iwate Medical University Hospital
  • SADZUKA Yasuyuki
    School of Pharmacy, Iwate Medical University

Bibliographic Information

Other Title
  • リポソーム製剤AmBisome<sup>®</sup>の医療現場における有用性と改善点
  • リポソーム製剤AmBisomeの医療現場における有用性と改善点
  • リポソーム セイザイ AmBisome ノ イリョウ ゲンバ ニ オケル ユウヨウセイ ト カイゼンテン

Search this article

Abstract

  We have studied AmBisome®, which is amphotericin B containing liposomes, used in the treatment of mycosis. Any potential problems regarding the liposome formulation remain unknown because it is a new dosage form. AmBisome® is useful in that it can decrease adverse reactions while maintaining a therapeutic effect. However, it is doubtful whether AmBisome® is suitable in a busy clinical environment. For example, this formulation should be filtered with an established filter. We then carried out a questionnaire survey involving medical staff (doctors and nurses) to clarify the problems regarding the liposome formulation and its practical utilization. Most doctors were satisfied with the effect of AmBisome®, but about 90% of nurses who had used the preparation answered that it was troublesome to use the filter. On the other hand, only 40% of doctors understood how to use the filter when AmBisome® was made up; 14% of nurses also did not know how to use the filter. We thought this was because they were not shown how to use it; actually, 30% of doctors were shown the preparation method by medical representatives (MR), although no nurse received an explanation. The residual rate of amphotericin B on 100 used filter pieces differed 50-fold between the minimum and maximum values. AmBisome® is effective as an antifungal agent. However, pharmaceutical companies must liaise with medical staff for its effective clinical use. We hope that such companies will have exchanges with medical staff to develop safe and simple medicines, and that liposomes will be effective for many patients.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 130 (3), 457-461, 2010-03-01

    The Pharmaceutical Society of Japan

References(3)*help

See more

Details 詳細情報について

Report a problem

Back to top